Dr Nicole van der Weerden appointed acting CEO
Arovella Therapeutics Ltd (ASX: ALA), (Arovella or the Company) advises that following the ASX announcement of 4 May 2026 that Dr Michael Baker resigned as Chief Executive Officer, the Board accepted his resignation and terminated his employment.
The Company has appointed Dr Nicole Van Der Weerden as Acting Chief Executive Officer effective today.
“I am extremely excited to lead Arovella in the lead up to our phase I trial of our lead CAR-iNKT cell therapy candidate, ALA-101. My team and I are very much up for the challenge and believe the coming period represents a significant opportunity to demonstrate the potential of our technology and to deliver meaningful value for both patients and shareholders as we advance towards the clinic.” said Dr. Van Der Weerden.
Arovella’s Chairman, Mr David Williams, said: “It is understating it to say we are very fortunate to have Nicole to step into the role. Last night, she led a Senior Executive strategy meeting at ISCT 2026 in Dublin and the board was invited. Nicole is very impressive and also has an impressive team with her. The Board and I will provide her with any support she requires. I am very much looking forward to working together.”
Dr. Van Der Weerden’s salary will be increased to match Dr Baker’s salary of $386,250 plus superannuation. Arovella will update the market on the CEO search process in due course.